DE60324431D1 - Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs - Google Patents

Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs

Info

Publication number
DE60324431D1
DE60324431D1 DE60324431T DE60324431T DE60324431D1 DE 60324431 D1 DE60324431 D1 DE 60324431D1 DE 60324431 T DE60324431 T DE 60324431T DE 60324431 T DE60324431 T DE 60324431T DE 60324431 D1 DE60324431 D1 DE 60324431D1
Authority
DE
Germany
Prior art keywords
cancer
cyclyl
gnrh
alkylaminoalkyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60324431T
Other languages
English (en)
Inventor
Thomas Geoffrey Bird
Matthias Ferdinand Herdemann
Mickael Louis Maudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60324431D1 publication Critical patent/DE60324431D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60324431T 2002-08-21 2003-08-19 Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs Expired - Fee Related DE60324431D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292077 2002-08-21
PCT/GB2003/003633 WO2004017961A2 (en) 2002-08-21 2003-08-19 Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer

Publications (1)

Publication Number Publication Date
DE60324431D1 true DE60324431D1 (de) 2008-12-11

Family

ID=31896982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324431T Expired - Fee Related DE60324431D1 (de) 2002-08-21 2003-08-19 Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs

Country Status (10)

Country Link
US (1) US7514570B2 (de)
EP (1) EP1531811B1 (de)
JP (1) JP2006505528A (de)
AR (1) AR041030A1 (de)
AT (1) ATE412412T1 (de)
AU (1) AU2003255820A1 (de)
DE (1) DE60324431D1 (de)
ES (1) ES2314277T3 (de)
TW (1) TW200413351A (de)
WO (1) WO2004017961A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523145A (ja) * 2004-02-20 2007-08-16 アストラゼネカ アクチボラグ ゴナドトロピン放出ホルモン（ｇｎｒｈ）アンタゴニストとしてのピロール誘導体
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2576144C (en) 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
DK1781618T3 (da) 2004-08-27 2012-10-29 Esteve Labor Dr Sigma-receptorinhibitorer
EP1829875A1 (de) 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazolderivate als Inhibitoren des Sigma-Rezeptors
EP1829866A1 (de) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Inhibitoren von Sigmarezeptoren
EP1829867A1 (de) 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Gegenüber dem Sigmarezeptor pharmazeutisch aktive Imidazolverbindungen
EP2116539A1 (de) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2353598A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz
EP2353591A1 (de) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
EP2388005A1 (de) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
EP2395003A1 (de) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazolverbindungen als Sigmarezeptor-Inhibitoren
EP2415471A1 (de) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
EP2524694A1 (de) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
TN2016000228A1 (en) 2013-12-17 2017-10-06 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS.
CN104557711B (zh) * 2014-12-26 2017-12-15 南通大学 含fts结构的吡唑肟类化合物的制备和应用
EP3886854A4 (de) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ183298A3 (cs) 1995-12-14 1998-09-16 Merck And Co., Inc. Nepeptidové deriváty, antagonizující hormon, uvolňující gonadotropin
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU707277B2 (en) 1995-12-14 1999-07-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2240115A1 (en) 1995-12-14 1997-06-19 Wallace T. Ashton Antagonists of gonadotropin releasing hormone
CN1208412A (zh) 1995-12-14 1999-02-17 麦克公司 促性腺激素释放激素拮抗剂
JPH10287655A (ja) 1997-04-10 1998-10-27 Kaken Pharmaceut Co Ltd ピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1998055470A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0994708A1 (de) 1997-06-05 2000-04-26 Merck & Co., Inc. Antagonisten des gonadotropin freisetzenden hormones
JP2002503252A (ja) 1997-06-05 2002-01-29 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモンの拮抗薬
WO1998055479A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0986385A4 (de) 1997-06-05 2001-05-16 Merck & Co Inc Antagonisten des gonadorelins
US6156772A (en) 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2308069A1 (en) 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1999021553A1 (en) 1997-10-28 1999-05-06 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002503660A (ja) 1998-02-11 2002-02-05 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
WO1999041252A1 (en) 1998-02-11 1999-08-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2002510684A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
WO1999051234A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1067929A1 (de) 1998-04-02 2001-01-17 Merck & Co., Inc. Gonadotropin-releasing-hormon antagonisten
CA2326140A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3210799A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2326143A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69915862T2 (de) * 1998-11-20 2004-08-05 G.D. Searle Llc Verfahren zur herstellung 5-substituierter pyrazole unter verwendung von dithietane
EP1165075A4 (de) 1999-03-10 2002-04-10 Merck & Co Inc 6-azaindolverbindungen als antagonisten des gonadoliberins
CA2367130A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3868800A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
WO2000053181A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1161431A4 (de) 1999-03-10 2002-04-24 Merck & Co Inc 6-azaindol-verbindungen als antagonisten des gonadotropin-freisetzungs hormones
JP2002538204A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
US6583153B2 (en) 2000-12-12 2003-06-24 Ortho-Mcneil Pharmaceutical, Inc. 7-heterocyclyl quinoline and thieno[2,3-b]yridine derivatives useful as antagonists of gonadotropin releasing hormone
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
MXPA04005999A (es) 2001-12-21 2005-07-13 Taisho Pharma Co Ltd Derivado de piperazina.

Also Published As

Publication number Publication date
AU2003255820A1 (en) 2004-03-11
EP1531811B1 (de) 2008-10-29
AR041030A1 (es) 2005-04-27
WO2004017961A3 (en) 2004-04-08
EP1531811A2 (de) 2005-05-25
ES2314277T3 (es) 2009-03-16
ATE412412T1 (de) 2008-11-15
JP2006505528A (ja) 2006-02-16
US20060287379A1 (en) 2006-12-21
WO2004017961A2 (en) 2004-03-04
TW200413351A (en) 2004-08-01
US7514570B2 (en) 2009-04-07
AU2003255820A8 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
HK1096392A1 (en) Substituted heterocycles
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
HK1102544A1 (en) Use of herbal compositions in the manufacture of medicine for treating prostate cancer
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
WO2003087831A3 (en) Proteins involved in breast cancer
DE60033649D1 (de) Verbindungen und therapeutische methoden
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
IS2869B (is) Notkun fúlvestrants við meðhöndlun á þrálátu brjóstakrabbameini
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee